Universal Donor TGFβi Natural Killer Cells(Nationwide Children'S Hospital)

N/A

Report date: 2026/04/25 20:00:23

Base Information

Drug NameUniversal Donor TGFβi Natural Killer Cells(Nationwide Children'S Hospital)
Drug Alias NameUniversal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells(Nationwide Children'S Hospital)UD TGFβi NK cells(Nationwide Children'S Hospital)UD TGFβi NK cell product(Nationwide Children'S Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsBrain Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNationwide Children'S HospitalRally FoundationWashington University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRally FoundationWashington University School Of MedicineNationwide Children'S Hospital
Active IndicationsN/A
Inactive IndicationsBrain Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A